Epcoritamab
- Generic Name
- Epcoritamab
- Brand Names
- Epkinly, Tepkinly
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2134641-34-0
- Unique Ingredient Identifier
- D6OMY2L0WA
- Background
Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells. Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cell–mediated killing of CD20+ malignant B cells. Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer comm...
- Indication
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under acc...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Associated Therapies
- -
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 180
- Registration Number
- NCT05660967
- Locations
- 🇺🇸
UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States
🇦🇹Kepler Universitätsklinikum, Linz, Austria
🇦🇹LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 900
- Registration Number
- NCT05578976
- Locations
- 🇺🇸
Orlando Health Cancer Institute /ID# 232626, Orlando, Florida, United States
🇺🇸University of Illinois at Chicago /ID# 226889, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland, United States
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 184
- Registration Number
- NCT05451810
- Locations
- 🇺🇸
Our Lady Of The Lake Regional Medical Center /ID# 255008, Baton Rouge, Louisiana, United States
🇺🇸Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 245003, Lebanon, New Hampshire, United States
🇺🇸OhioHealth Arthur G.H. Bing, MD Cancer Center /ID# 260803, Columbus, Ohio, United States
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 500
- Registration Number
- NCT05409066
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences /ID# 227198, Little Rock, Arkansas, United States
🇺🇸Beverly Hills Cancer Center /ID# 231535, Beverly Hills, California, United States
🇺🇸Valkyrie Clinical Trials /ID# 268502, Los Angeles, California, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 15
- Registration Number
- NCT05206357
- Locations
- 🇨🇿
Fakultní Nemocnice Brno - Jihlavská /ID# 239956, Brno, Brno-mesto, Czechia
🇺🇸Lucile Packard Children's Hospital /ID# 240854, Palo Alto, California, United States
🇺🇸Nicklaus Children's Hospital /ID# 241174, Miami, Florida, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- Conditions
- Interventions
- Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneDrug: rituximab and lenalidomideDrug: rituximab and bendamustineDrug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatinDrug: gemcitabine and oxaliplatinDrug: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisoneDrug: rituximab, ifosfamide, carboplatin, and etoposide phosphateDrug: LenalidomideBiological: Epcoritamab
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Genmab
- Target Recruit Count
- 543
- Registration Number
- NCT04663347
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 552
- Registration Number
- NCT04628494
- Locations
- 🇺🇸
Community Health Network Cancer Center North, Indianapolis, Indiana, United States
🇺🇸TriHealth Cancer Institute- Good Samaritan Hospital, Cincinnati, Ohio, United States
🇨🇳Beijing Cancer Hospital, Beijing, China
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 184
- Registration Number
- NCT04623541
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.